A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508701-24-00

Acronym

D910VC00001

Enrollment

131

Registered

2024-04-19

Start date

2022-11-21

Completion date

Unknown

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locoregional Hepatocellular Carcinoma (HCC)

Brief summary

Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR

Detailed description

Overall Survival (OS)

Interventions

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGINFLIXIMAB

DRUGLENVIMA 4 mg hard capsules

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGMYCOPHENOLATE MOFETIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR	—

Secondary

Measure	Time frame
Overall Survival (OS)	—

Countries

Belgium, France, Germany, Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026